ARAF S214C

CI-VAR-00004020Explore in graph →NP_001645.1:p.Ser214CysNM_001654.4:c.641C>GClinVar 376137 CIViC 10 rs1057519786

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma3
ARAF S214C	Sorafenib	Predictive	C	Supports Sensitivity Response	2	accepted	EID17 In one patient with S214C mutation, the use of sorafenib has led to more than 5 years of survival and near remission. PMID 24569458 · Imielinski et al., 2014 · Open in CIViC	civic
ARAF S214C	Sorafenib	Predictive	D	Supports Sensitivity Response	3	accepted	EID40 Sorafenib can inhibit ARF-mediated MEK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro. PMID 24569458 · Imielinski et al., 2014 · Open in CIViC	civic
ARAF S214C	Trametinib	Predictive

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Lung Neoplasm1
ARAF S214C	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	accepted	EID11147 194 somatic mutations seen in primary lung cancers were functionally evaluated using three approaches: (1) differences in pattern or extent of changes in gene expression in A549 cells induced by trans… (full text at CIViC) PMID 27478040 · Berger et al., 2016 · Open in CIViC	civic